Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

about

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.

P2860

Q55495617-97DD574A-1BD8-4CB6-AACD-EA91B2410639

P2860

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

Item

http://www.wikidata.org/entity/Q42287385

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

@en

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

@nl

type

Item

label

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

@en

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

@nl

prefLabel

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

@en

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

@nl

P1476

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

@en

P2093

Leo I Gordon

http://www.w3.org/2001/XMLSchema#string

Pamela B Allen

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

P304

1179554917731072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1179554917731072

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28989291

http://www.w3.org/2001/XMLSchema#string

P932

5624347

http://www.w3.org/2001/XMLSchema#string

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

about

P2860

P2860

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932